Bortezomib in Patients With Chronic Graft Versus Host Disease
Status:
Completed
Trial end date:
2018-04-09
Target enrollment:
Participant gender:
Summary
This study will investigate whether bortezomib can control the immune system and can be used
to treat GVHD. Bortezomib has been used with not too many serious side effects in patients
with multiple myeloma who will undergo transplant and also for acute graft versus host
disease.